Related Experiment Videos
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi1, Ryan Woods, Peter M Ravdin
1Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. ryerushalmi@bccancer.bc.ca
The Lancet. Oncology
|February 16, 2010
Summary
Ki67 is a key marker for early breast cancer, showing prognostic and predictive value. New evidence suggests Ki67 should be routinely included in pathological assessments to guide treatment decisions.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Current early breast cancer treatment relies on oestrogen-receptor, progesterone-receptor, and HER2 status.
- The American Society of Clinical Oncology guidelines do not mandate Ki67 testing.
- Emerging genetic tests highlight the significance of proliferative genes like Ki67.
Purpose of the Study:
- To re-evaluate evidence supporting the inclusion of Ki67 in standard early breast cancer pathological assessments.
- To provide an updated review of Ki67's prognostic and predictive roles.
- To inform about laboratory techniques for Ki67 determination.
Main Methods:
- Review of published literature and randomized studies.
- Retrospective analysis of existing data on Ki67.
- Assessment of evidence for guideline changes.
Main Results:
- Ki67 demonstrates significant prognostic and predictive value in early breast cancer.
- Randomized studies increasingly support the role of Ki67.
- New genetic tests underscore the importance of proliferative markers.
Conclusions:
- Ki67 is a crucial marker that warrants inclusion in routine pathological assessments for early breast cancer.
- Updated evidence suggests current guidelines may need revision to incorporate Ki67.
- Standardized Ki67 assessment can improve treatment recommendations.
